In this guide
Tirzepatide and semaglutide are different active ingredients used in prescription medicines. Comparing them starts with identifying the exact product, the reason for treatment and the evidence that applies to it. A headline about average weight loss cannot settle all three questions.
The most useful comparison gives you something concrete to discuss with a prescribing clinician: what was studied, how the products differ, which safety questions matter to you and what ongoing care would involve.
Start with the ingredient and the product
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors. These are hormone-signaling pathways; the mechanism alone does not tell you which prescription fits your medical history. 1, 2
Brand names add another layer. Zepbound contains tirzepatide and has an adult weight-management indication, as well as an indication for moderate to severe obstructive sleep apnea in adults with obesity. Wegovy contains semaglutide and has weight-management uses; its other approved uses depend on the formulation and patient population. Mounjaro and Ozempic are distinct tirzepatide and semaglutide products with type 2 diabetes indications. Their labeling should be read separately. 1, 2, 3, 4
Ask for the complete product name and formulation whenever a conversation uses only “tirzepatide,” “semaglutide” or “GLP-1.” This helps keep a study result, a prescription and a price quote connected to the right medicine. Our guide to tirzepatide, Zepbound and Mounjaro explains the naming distinctions in more detail.
What did the head-to-head trial find?
SURMOUNT-5 directly compared weekly injections in 751 adults without diabetes who had obesity, or overweight with a qualifying weight-related condition. Participants were randomly assigned to tirzepatide or semaglutide for 72 weeks. The study was open-label, so participants and investigators knew which treatment was assigned. Eli Lilly, tirzepatide’s manufacturer, funded it. 5, 6
| SURMOUNT-5 comparison | Tirzepatide | Semaglutide |
|---|---|---|
| Studied treatment | Once-weekly injection, maximum tolerated dose of 10 or 15 mg | Once-weekly injection, maximum tolerated dose of 1.7 or 2.4 mg |
| Estimated average body-weight change at week 72 | 20.2% reduction | 13.7% reduction |
These are study estimates for the assigned groups, not a dosing guide or a forecast for an individual. The primary endpoint was percentage change in body weight at week 72. Tirzepatide produced greater average weight reduction in that comparison. Both groups most commonly reported gastrointestinal adverse events, generally mild or moderate and mainly during dose escalation. 5
Keep the study’s boundaries attached to its findings. It did not establish the same comparison in people with diabetes, in every age group or with every formulation. The current Wegovy label also includes oral tablets and a 7.2 mg injection option; neither was the semaglutide treatment tested in SURMOUNT-5. 2, 5
That distinction matters when an older headline says one ingredient “beats” the other. A result for specified weekly injections over 72 weeks does not answer every current product question. Ask whether the comparison you are reading matches the option being discussed for you.
Which questions matter beyond average weight loss?
Bring your own priorities into the discussion. You might want to understand how a treatment relates to an existing condition, whether its daily or weekly routine is practical, or how side effects would be handled. Write those questions down before comparing percentages.
A useful appointment discussion can separate several decisions:
- Reason for treatment: Which diagnosis and treatment goal are being addressed, and which product’s approved uses apply?
- Evidence: Does the research include people with a medical history like yours, using the formulation under consideration?
- Experience: What would happen if the medicine is difficult to tolerate, or the response is different from what you hoped?
- Follow-up: Who would review progress, medication changes and concerns between appointments?
- Continuity: What would the plan be if coverage, affordability or the available product changes?
A comparison article can organize those questions. The prescribing decision needs the details of your health history and the actual prescription being considered.
What safety differences should you discuss?
The Zepbound and Wegovy labels both list nausea, vomiting, diarrhea and constipation among common adverse reactions. Both have warnings about pancreatitis, gallbladder problems, dehydration-related kidney injury and severe gastrointestinal problems; neither is recommended for severe gastroparesis. Discuss relevant history and other medicines before treatment. 1, 2
Both carry boxed warnings about thyroid C-cell tumors observed in animals; whether they cause these tumors in humans is unknown. A personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. 1, 2
Pregnancy plans deserve a separate conversation. Wegovy’s weight-management labeling calls for stopping at least two months before a planned pregnancy. Zepbound’s label advises people using oral hormonal contraception to use a non-oral method or add a barrier method for four weeks after starting and after each dose increase. These instructions are product-specific. 1, 2
Tell the clinician about insulin or sulfonylureas, which can increase low-blood-sugar risk with these medicines, and about planned anesthesia or deep sedation. Ask for written instructions on symptoms that require prompt care. This is a selection of discussion points, not the complete safety information or a screening checklist. 1, 2
How do compounded preparations fit into the comparison?
Compounded tirzepatide or semaglutide should be identified separately from FDA-approved branded medicines. FDA states that compounded drugs are not FDA approved and do not undergo its premarket review for safety, effectiveness or quality. 7
A shared ingredient name does not establish that a compounded preparation has the same clinical evidence as the product used in a trial. Do not apply SURMOUNT-5’s averages to an unspecified compounded preparation or treat it as a head-to-head study of compounded products.
If compounding is part of the discussion, ask what exact preparation is proposed, why it is being considered and which evidence applies. FDA recommends compounded drugs only when a patient’s medical needs cannot be met by an FDA-approved drug. This article does not establish that circumstance for any reader. 7
Compare the care plan and the full cost
Ask for a written quote that identifies the product, quantity, billing period and included care. Clarify consultation, laboratory, follow-up and renewal charges, and ask which amounts could change later. A medication-only quote and a quote that includes appointments need different comparison notes.
Insurance and savings questions should name the exact product and the intended use. Ask the insurer or offer administrator to confirm your own eligibility and current terms before relying on a quoted price. Our tirzepatide cost guide offers a practical way to compare these components without assuming a standard package.
Everyday handling also deserves its own questions. The timing guide and storage and expiration guide explain why instructions need to stay attached to the actual product. Bring unresolved questions about your own prescription to the prescribing clinician or pharmacist.
Questions to bring to your clinician
You do not need to arrive having chosen a medication. You can arrive with a short list:
- Which exact product and formulation are we discussing, and why?
- Which research applies to my situation, and which results would be misleading to assume?
- How do my medical history, other medicines and pregnancy plans affect the options?
- What follow-up and written safety instructions would I receive?
- What is the full cost over the same period, and what could change?
- What would we reassess if treatment is poorly tolerated or the plan becomes difficult to continue?
Use the answers to build a clear picture of the proposed treatment. Average trial results are one part of that picture; the prescription, precautions and care plan need to make sense for you together.
Common questions about tirzepatide and semaglutide
Are tirzepatide and semaglutide the same medicine?
No. They are different active ingredients. Semaglutide activates GLP-1 receptors; tirzepatide activates GIP and GLP-1 receptors. Identify the full product name rather than treating the ingredient names as interchangeable. 1, 2
Does SURMOUNT-5 mean tirzepatide is best for everyone?
No. It supports greater average weight reduction with the studied tirzepatide regimen in that trial population. It does not choose a treatment for every person or compare all current semaglutide formulations and doses. 5
Can I convert a semaglutide dose into a tirzepatide dose?
The trial’s treatment arms do not provide a personal dose-conversion rule. If a change is being considered, ask the prescriber for an individual plan; do not use the study table to calculate a substitute dose.
Can I take both together?
The Zepbound and Wegovy labels do not recommend combining them with other GLP-1 receptor agonists. Discuss any proposed change with your prescriber rather than adding one medicine to the other. 1, 2
Do the trial percentages apply to compounded medications?
The trial does not establish comparable outcomes for an unspecified compounded preparation. Compounded drugs are distinct from FDA-approved products and are not FDA approved. 7
Sources
- Zepbound prescribing information, Eli Lilly. Revised August 2026; checked October 15, 2026.
- Wegovy prescribing information, Novo Nordisk. Revised June 2026; checked October 15, 2026.
- Mounjaro prescribing information, Eli Lilly. Checked October 15, 2026.
- Ozempic prescribing information, Novo Nordisk. Revised May 2026; checked October 15, 2026.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, Aronne LJ et al., New England Journal of Medicine, 2025;393:26–36. DOI: 10.1056/NEJMoa2416394. Primary trial abstract checked October 15, 2026.
- SURMOUNT-5, NCT05822830, ClinicalTrials.gov. Registry eligibility, treatment arms and endpoints checked October 15, 2026.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA. Checked October 15, 2026.